TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. The Company is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two Food and Drug Administration (FDA)-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 143.91% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 45.15M.
Fairly Valued
The company’s latest PE is -3.30, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 14.73M shares, increasing 17.64% quarter-over-quarter.
Held by Chuck Royce
Star Investor Chuck Royce holds 250.86K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.36.